Molecularly Targeted Therapy for Soft Tissue Sarcoma in Texas - Biospecimen Banking Protocol
This bio-specimen protocol is a part of a Cancer Prevention and Research institute of Texas (CPRiT) funded, multi-institutional study to identify actionable mutations in pediatric sarcoma (ewing sarcoma and Soft tissue sarcoma), to study identified mutations in real time using mammalian and non-mammalian model systems and to establish the feasibility of bringing molecularly targeted therapy to routine clinical practice. The bio-specimen study will provide the system for procuring tissue and clinical information necessary from multiple sites to achieve the goals of the overall project.
Patients will be asked to consent to the optional release of de-identified data into databases.
- The eligibility criteria listed are interpreted literally and cannot be waived.
- All clinical and laboratory data required for determining eligibility of the patient's enrolled on this trial must be available in the patient's medicalxresearch records which will serve as the source document for verification at the time of audit.
- Patient will be younger than 50 years of age at the time of enrollment
- Patient's most of one of the following histologically confirmed diagnosis: Rhabdomyosarcoma,
non-rhabdomyosarcoma soft tissue sarcoma (refer to appendix 1 for complete listing), Ewing sarcoma family tumor which includes Ewing sarcoma bone, non-osseous Ewing sarcoma, Askin tumor and peripheral neural ectodermal tumor of bone or soft tissue